MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

NCT06612775 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-09-25

No results posted yet for this study

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Conditions

  • Focal Epilepsy

Interventions

DRUG

Test drug CB03-154 5mg group

CB03-154 tablet (5mg/tablet) once daily.

DRUG

Test drug CB03-154 10mg group

Two CB03-154 tablets (5mg/tablet) once daily.

DRUG

Test drug CB03-154 20mg group

Four CB03-154 tablets (5mg/tablet) once daily.

DRUG

Placebo group

Four Placebo tablets once daily.

Sponsors & Collaborators

  • Shanghai Zhimeng Biopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-08-31
Completion
2026-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612775 on ClinicalTrials.gov